Combination of PVSRIPO and Atezolizumab for Adults With Recurrent Malignant Glioma

Sponsor
Darell Bigner
Study ID
NCT03973879
Phase
PHASE1/PHASE2
Status
Withdrawn

Conditions

  • Malignant Glioma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • PVSRIPO — BIOLOGICAL
    Oncolytic polio/rhinovirus recombinant
  • Atezolizumab — DRUG
    Antibody

Study Details

This study evaluates the safety of PVSRIPO treatment in combination with Atezolizumab in patients with WHO grade IV malignant glioma. All patients will receive a single PVSRIPO infusion followed by atezolizumab infusions every three weeks for up to two years.

Key Dates

Start date
Feb 29, 2020
Status verified
Feb 2020
Primary completion
Jan 31, 2024
Completion
Jan 31, 2024

Study Design

Enrollment
0 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: PVSRIPO + Atezolizumab
    Single PVSRIPO infusion at a dose of 5x10\^7 tissue culture infected dose (TCID50). Atezolizumab infusions at a dose of 1200 mg every three weeks for up to two years.

Primary Outcome Measure

Number of unacceptable adverse events [ Time Frame: 14 days after first atezolizumab treatment ]

Related Studies